Pramodini Medicare Share Price & Earnings Call Analysis
- Market cap
- ₹238 Cr
- P/E
- 13.69
- ROE
- 39.09%
- PEG
- 0.33
- Price to sales
- 3.82
- Debt to equity
- 0.34
- 52W high / low
- ₹137 / ₹104
- EBITDA margin
- 49.61%
- Net profit margin
- 27.90%
- Promoter holding
- 62.64%
- Sales (last year)
- ₹62 Cr
Incorporated in 2000, Pramodini Medicare Limited is a diagnostic service provider in India offering technology-enabled diagnostic services across radiology, clinical laboratory, and nuclear medicine segments.[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹921 Cr | — | |
| 2 | 40%+ | Flat | ₹575 Cr | 21.9 | |
| 3 | Aster DM Quality Care Ltd | 20–40% | Up 2%+ | ₹59,405 Cr | 164.6 |
| 4 | 20–40% | Up 2%+ | ₹551 Cr | 18.5 | |
| 5 | 20–40% | Up 0–2% | ₹1,635 Cr | 16.5 | |
| 6 | 20–40% | Flat | ₹1.21L Cr | 57.7 |
Sign up free to see every company in the sector ranking and track Pramodini Medicare.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingFinancials of Pramodini Medicare
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Pramodini Medicare
Shareholding breakup across reporting periods.
| Aug 2026 | |
|---|---|
| Promoters + | 62.64% |
| FIIs + | 2.84% |
| DIIs + | 8.64% |
| Public + | 25.88% |
| No. of Shareholders | 1,144 |
Financials of Pramodini Medicare
Quarterly Results
Quarter-by-quarter operating performance
| Sales + |
| Expenses + |
| Operating Profit |
| OPM % |
| Other Income + |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| Net Profit + |
| EPS in Rs |
Financials of Pramodini Medicare
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 25 | 31 | 35 | 38 | 62 |
| Expenses + | 13 | 16 | 20 | 17 | 31 |
| Operating Profit | 12 | 15 | 16 | 21 | 31 |
| OPM % | 49% | 49% | 44% | 55% | 50% |
| Other Income + | 0 | 0 | 1 | 0 | 1 |
| Interest | 2 | 2 | 2 | 1 | 1 |
| Depreciation | 4 | 5 | 4 | 4 | 7 |
| Profit before tax | 7 | 8 | 10 | 16 | 23 |
| Tax % | 29% | 27% | 29% | 29% | 25% |
| Net Profit + | 5 | 6 | 7 | 11 | 17 |
| EPS in Rs | 4.92 | 4.76 | 5.40 | 85.89 | 10.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Pramodini Medicare
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 17 |
| Reserves | 10 | 18 | 23 | 34 | 36 |
| Borrowings + | 25 | 21 | 12 | 11 | 18 |
| Other Liabilities + | 6 | 9 | 12 | 10 | 23 |
| Total Liabilities | 41 | 50 | 49 | 56 | 94 |
| Fixed Assets + | 26 | 22 | 16 | 22 | 44 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 15 | 27 | 33 | 35 | 49 |
| Total Assets | 41 | 50 | 49 | 56 | 94 |
Financials of Pramodini Medicare
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 12 | 12 | 10 | 22 | 25 |
| Cash from Investing Activity + | -12 | -12 | -1 | -15 | -31 |
| Cash from Financing Activity + | 3 | 3 | -11 | -2 | 6 |
| Net Cash Flow | 3 | 3 | -2 | 5 | 0 |
| Free Cash Flow | -0 | -0 | 9 | 12 | -4 |
| CFO/OP | 113% | 93% | 83% | 127% | 98% |
Financials of Pramodini Medicare
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 109 | 172 | 186 | 107 | 102 |
| Inventory Days | |||||
| Days Payable | |||||
| Cash Conversion Cycle | 109 | 172 | 186 | 107 | 102 |
| Working Capital Days | -66 | -36 | 16 | -0 | 2 |
| ROCE % | 27% | 30% | 41% | 42% |
Continue your research
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q2 FY27)
Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves
- Shalby (Q2 FY27)
Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S
- Metropolis Healt (Q2 FY27)
Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre
- Nephrocare Health Services (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Key investor presentation takeaways from Nephrocare Health Services